CN108776226A - Early onset preeclampsia rapid screening test paper and kit - Google Patents
Early onset preeclampsia rapid screening test paper and kit Download PDFInfo
- Publication number
- CN108776226A CN108776226A CN201810541008.7A CN201810541008A CN108776226A CN 108776226 A CN108776226 A CN 108776226A CN 201810541008 A CN201810541008 A CN 201810541008A CN 108776226 A CN108776226 A CN 108776226A
- Authority
- CN
- China
- Prior art keywords
- apela
- test paper
- urine
- blood
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a kind of Early onset preeclampsia screening test paper, it includes the optional test paper for detecting APELA concentration in blood or urine.The invention also discloses a kind of Early onset preeclampsia screening kit, it includes the optional reagent for detecting APELA concentration in blood or urine.The invention also discloses purposes of the test paper of APELA concentration in detection blood or urine in preparing Early onset preeclampsia screening test paper.The invention also discloses purposes of the reagent of APELA concentration in detection blood or urine in preparing Early onset preeclampsia screening reagent.Early onset preeclampsia rapid screening test paper disclosed by the invention and kit, only need acquisition blood samples of patients or urine, can screening patient whether suffer from Early onset preeclampsia, it can be used for clinical assistant diagnosis, it can noninvasive, effectively and quickly examine screening onset preeclampsia, easy to use, potential applicability in clinical practice is good.
Description
Technical field
The present invention relates to Early onset preeclampsia rapid screening test paper and kits.
Background technology
Preeclampsia, (preeclampsia) belonged to the scope of hypertensive disorder in pregnancy, was a kind of the more of gestational period spy hair
Systemic disease.Preeclampsia shows as pregnant woman's hypertension, Urine proteins, companion or without multiple organ injury, fetal growth restriction, tire
Youngster's distress, hapamnion seriously threaten female viviparous life.The incidence of pre-eclampsia is about 5%~8%, according to the pregnant week of generation
It is divided into premature severe preeclampsia and Early onset preeclampsia, 34 pregnant weeks are the line that defines of Early onset and late hair style, and morbidity is pregnant in 34
It was referred to as premature severe preeclampsia before week, is known as Early onset preeclampsia after 34 pregnant weeks.Wherein Early onset preeclampsia accounts for
The refined overwhelming majority of tendency accounts for about 90%, therefore accurate screening Early onset preeclampsia seems extremely important.
Main method currently on the market can only be made by hypertension and proteinuria these illnesss through experienced doctor
Speculate, come whether screening patient belongs to preeclampsia in late period illness, there is presently no occur one to carry out qualitative, quantitative
Index carries out the screening of patient PE.Therefore, clinically it is badly in need of the mark of noninvasive, effective, quick preeclampsia screening
Object, and our this kit just fills up this blank.
Invention content
To solve the above problems, the present invention provides the test paper of Early onset preeclampsia screening and kits.
The present invention provides Early onset preeclampsia screening test paper, it includes optional for detecting in blood or urine
The test paper of APELA concentration.
Wherein, the test paper for detecting APELA concentration in blood or urine is colloidal gold detection test paper.
Further, above-mentioned colloidal gold detection test paper, including PVC bottom plates and nitrocellulose filter, nitrocellulose filter
It is arranged on PVC bottom plates, further includes the sample pad being successively set on nitrocellulose filter, colloidal gold pad, detection zone, quality control region
And water absorption pad.
Further, above-mentioned colloidal gold detection test paper is provided with one layer of colloid gold label in the colloidal gold pad
APELA polyclonal antibody layers.
Further, above-mentioned colloidal gold detection test paper is provided with one layer of APELA artificial antigen on the detection zone
Layer.
Further, above-mentioned colloidal gold detection test paper, the quality control region are provided with one layer of goat anti-rabbit antibody layer.
The present invention also provides Early onset preeclampsia rapid screening kits, it is characterised in that：It includes optional
Reagent for detecting APELA concentration in blood or urine.
Wherein, the reagent for detecting APELA concentration in blood or urine is ELISA detection reagents.
The present invention also provides the test paper of APELA concentration in detection blood or urine to prepare Early onset preeclampsia screening
With the purposes in test paper.
Wherein, the test paper for detecting APELA concentration in blood or urine is colloidal gold detection test paper.
The present invention also provides the reagents of APELA concentration in detection blood or urine to prepare Early onset preeclampsia screening
With the purposes in reagent.
Wherein, the reagent for detecting APELA concentration in blood or urine is ELISA detection reagents.
In the present invention, the APELA is the ligand of g protein coupled receptor Apelin receptors.
The present inventor by analyzing the blood and urine of clinical Early onset, Early onset preeclampsia puerpera and Normal Parturients,
It was found that secreted polypeptide APELA in Early onset preeclampsia pregnant woman blood and urine concentration compared with Normal Parturients and Early onset eclampsia
Early period, puerpera was substantially reduced, thus can be by APELA concentration in detection pregnant woman blood or urine come pregnant woman described in rapid screening
Whether Early onset preeclampsia is suffered from.
Early onset preeclampsia rapid screening test paper provided by the invention and kit, can with screening pregnant woman to be checked whether
With Early onset preeclampsia：If a concentration of 0-8ng/ml in a concentration of 0-25ng/ml of APELA or urine in subject's blood,
Then determine that the risk that person to be checked suffers from Early onset preeclampsia is big；Conversely, the risk for then suffering from Early onset preeclampsia is small.The present invention tries
Paper and kit only need acquisition blood samples of patients or urine, so that it may which whether screening patient suffers from Early onset preeclampsia, can be used for facing
Bed auxiliary diagnosis, can noninvasive, effectively and quickly screening Early onset preeclampsia, easy to use, potential applicability in clinical practice is good.
Obviously, the above according to the present invention is not being departed from according to the ordinary technical knowledge and customary means of this field
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification, replacement or change of other diversified forms can also be made.
The specific implementation mode of form by the following examples remakes further specifically the above of the present invention
It is bright.But the range that this should not be interpreted as to the above-mentioned theme of the present invention is only limitted to example below.It is all to be based on the above of the present invention
The technology realized all belongs to the scope of the present invention.
Description of the drawings
APELA concentrations versus in the non-pregnant women of Fig. 1 and normal pregnancies blood
APELA concentrations versus in Fig. 2 Advanced pregnants normal pregnancies and late period PE pregnant woman blood
APELA concentrations versus in Fig. 3 early stages PE pregnant woman and late period PE pregnant woman blood
APELA concentrations versus in Fig. 4 Advanced pregnants normal pregnancies and early stage PE pregnant woman blood
APELA concentrations versus in the non-pregnant women of Fig. 5, normal pregnancies and late period PE pregnant woman urine
The present invention relates to APELA concentration test paper structural maps in detection pregnant woman blood or urine by Fig. 6
Specific implementation mode
APELA concentrations versus in the non-pregnant women of embodiment 1, normal pregnancies, early stage PE pregnant woman and late period PE pregnant woman blood
1, sample：Non- pregnant women 7, early pregnancy normal pregnancies 34, mid pregnancy normal pregnancies 18, Advanced pregnant
Normal pregnancies 15, late period PE pregnant woman 21, early stage PE pregnant woman 14；Above-mentioned late period PE pregnant woman and early stage PE pregnant woman were by 15 years
The gynemetrics chief physician of the above clinical experience is diagnosed as late period PE or early stage PE, with a high credibility.
2, in subject's blood APELA concentration detection method：
(1) serum extracts
Vein haemospasia 2-3mL, is not added with anti-coagulants, is placed at room temperature for 30min, and 2500rpm is centrifuged serum transfers after 5min extremely
New EP pipes, -80 DEG C of preservations after packing.
(2) ELISA is detected
APELA Human ELA ELISA kits (Phoenix Pharmaceuticals, Inc in serum.Article No.
EK-007-19 it) detects.It is as follows：
1. standard items, blood sample and the positive control of 50 μ L is added in advance coated protein-bonded 96 hole of secondary,
Then the polypeptide of the first binding protein and 25uL biotins (Biotin) label of 25uL is sequentially added；
2. (20-23 DEG C) of room temperature is incubated 2 hours；
3. after abandoning liquid, being cleaned 4 times with 1 × analysis buffers of 350uL (Assay Buffer)；
4. 100uL DE SA-HRP solution is added；
5. incubation at room temperature 1 hour；
6. after abandoning liquid, being cleaned 4 times with 1 × analysis buffers of 350uL (Assay Buffer)；
7. 100uL substrate solutions are added；
8. incubation at room temperature 1 hour；
9. terminating reaction with 100uL 2N HCl；
10. microplate reader reads 450nm light absorption values, standard curve is drawn with software Elisacacl, and calculate APELA concentration.
3, testing result is to when conclusion
Testing result is as follows：
APELA concentrations versus in the non-pregnant women of table 1 and normal pregnancies blood
It can be seen that by table 1 and Fig. 1, APELA is very low in the blood middle concentration of non-pregnant women, normally pregnant in the early, middle and late pregnancy period
Concentration in woman's blood is all higher, and is in the trend increased with the APELA concentration in pregnant woman blood that increases of pregnancy time.
APELA concentrations versus in 2 Advanced pregnant normal pregnancies of table and late period PE pregnant woman blood
Table 2 and Fig. 2 can be seen that late period PE pregnant woman is than the APELA concentration relative reductions in Advanced pregnant normal pregnancies blood
It is many.
APELA concentrations versus in table 3 early stage PE pregnant woman and late period PE pregnant woman blood
Table 3 and Fig. 3 can be seen that late period PE pregnant woman is more many than the APELA concentration relative reduction in early stage PE pregnant woman blood.
APELA concentrations versus in 4 Advanced pregnant normal pregnancies of table and early stage PE pregnant woman blood
Table 4 and Fig. 4 can be seen that the APELA concentration in Advanced pregnant normal pregnancies and early stage PE pregnant woman blood is comparatively
Without too big difference.
Above-mentioned description of test, secreted polypeptide APELA in Early onset preeclampsia pregnant woman blood concentration compared with Normal Parturients
Puerpera is substantially reduced with premature severe preeclampsia, thus can be by APELA concentration in detection pregnant woman blood come rapid screening institute
State whether pregnant woman suffers from Early onset preeclampsia.
APELA concentrations versus in the non-pregnant women of embodiment 2, normal pregnancies and late period PE pregnant woman urine
1, sample：Non- pregnant women 2, early pregnancy normal pregnancies 7, mid pregnancy normal pregnancies 7, Advanced pregnant are just
Normal pregnant woman 8, late period PE pregnant woman 4；Above-mentioned late period PE pregnant woman and early stage PE pregnant woman are produced by the woman of 15 years or more clinical experiences
Head of the department's doctor diagnosed is late period PE or early stage PE, with a high credibility.
2, in subject's urine APELA concentration detection method：
Fresh urine sample centrifuges 15-20min in 4 DEG C of 2500rpm, retains supernatant, and -20 or -80 preserve.
APELA Human ELA ELISA kits (Phoenix Pharmaceuticals, Inc in urine.Article No.
EK-007-19 it) detects.It is as follows：
1. it is right that the standard items of 50 μ L, urine sample and the positive are added in advance coated protein-bonded 96 hole of secondary
According to, then sequentially add 25uL first binding protein and 25uL biotins (Biotin) label polypeptide；
2. (20-23 DEG C) of room temperature is incubated 2 hours；
3. after abandoning liquid, being cleaned 4 times with 1 × analysis buffers of 350uL (Assay Buffer)；
4. 100uL DE SA-HRP solution is added；
5. incubation at room temperature 1 hour；
6. after abandoning liquid, being cleaned 4 times with 1 × analysis buffers of 350uL (Assay Buffer)；
7. 100uL substrate solutions are added；
8. incubation at room temperature 1 hour；
9. terminating reaction with 100uL 2N HCl；
10. microplate reader reads 450nm light absorption values, standard curve is drawn with software Elisacacl, and calculate APELA concentration.
3, testing result is to when conclusion
Testing result is as follows：
APELA concentrations versus in the non-pregnant women of table 5, normal pregnancies and late period PE pregnant woman urine
Table 5 and Fig. 5 can be seen that APELA late PE pregnant woman than early pregnancy, mid pregnancy and Advanced pregnant pregnant woman
Concentration relative reduction in urine is many.
Above-mentioned description of test, secreted polypeptide APELA in Early onset preeclampsia pregnant woman urine concentration compared with Normal Parturients
Puerpera is substantially reduced with premature severe preeclampsia, thus can be by APELA concentration in detection pregnant woman urine come rapid screening institute
State whether pregnant woman suffers from Early onset preeclampsia.
The composition and application method of APELA Concentration Reagent boxes in 3 present invention detection pregnant woman blood of embodiment or urine
1, the composition of kit
Detection kit (50 person-portion)
| Component | Volume |
| Secondary binding protein | |
| APELA standard items | 2500uL |
| First binding protein | 1250uL |
| The polypeptide of biotin (Biotin) label | 1250uL |
| Analysis buffer (Assay Buffer) | 52500uL |
| DE SA-HRP solution | 5000uL |
| Substrate solution | 5000uL |
| Terminate liquid (2N HCl) | 5000uL |
2, the application method of kit
(1) serum extracts
Vein haemospasia takes urine 2-3mL, is not added with anti-coagulants, is placed at room temperature for 30min, and 2500rpm is centrifuged blood after 5min
Clear or urine is transferred to new EP pipes, -80 DEG C of preservations after packing.
(2) ELISA is detected
It is as follows：
①Standard items, blood sample or the urine sample and the positive of 50uL are added in advance coated protein-bonded 96 hole of secondary
Then control is included in the polypeptide of the first binding protein and 25uL biotins (Biotin) label of 25uL successively again；
2. (20-23 DEG C) of room temperature is incubated 2 hours；
3. after abandoning liquid, being cleaned 4 times with 1 × analysis buffers of 350uL (Assay Buffer)；
4. 100uLDE SA-HRP solution is added；
5. incubation at room temperature 1 hour；
6. after abandoning liquid, being cleaned 4 times with 1 × analysis buffers of 350uL (Assay Buffer)；
7. 100uL substrate solutions are added；
8. incubation at room temperature 1 hour；
9. terminating reaction with 100uL 2N HCl；
10. microplate reader reads 450nm light absorption values, standard curve is drawn with software Elisacacl, and calculate APELA concentration.
The composition and application method of APELA concentration test paper in 4 present invention detection pregnant woman blood of embodiment or urine
1, the composition of test paper
Test paper composition is as shown in Figure 5.Including consisting of part：
(1) sample pad；
(2) colloidal gold pad；
(3) detection zone T；
(4) quality control region C；
(5) nitrocellulose filter；
(6) water absorption pad (water-absorbent material)；
(7) PVC bottom plates.
The conjugate of APELA polyclonal antibodies-colloidal gold is coated in the gold-labelled pad of test strips, in the detection line of NC films
Position is fixed with APELA artificial antigens, and goat anti-rabbit antibody (identification APELA polyclonal antibodies are fixed in Quality Control line position
Secondary antibody).The APELA antigens and detectable substance for detecting line position are same substances, can compete the binding site of identification antibody.
When detection, if the APELA concentration in sample to be tested in detectable substance blood is in 25ng/ml or more or urine
APELA concentration is in 8ng/ml or more, and when sample to be tested flows through gold-labelled pad, the conjugate of APELA polyclonal antibodies-colloidal gold is just
It can be combined with detectable substance, the recognition site detected material of antibody cannot be artificial with the APELA that detects line position after occupying
Synthetic antigen combines, to be not in red lines in detection line.
If APELA concentration APELA concentration in the range of 0-25ng/ml or in urine in detectable substance blood in sample to be tested
Within the scope of 0-8ng/ml, the binding site of the conjugate of APELA polyclonal antibodies-colloidal gold in gold-labelled pad would not be occupied
According to, when flowing through detection line can with detection line position APELA artificial antigens be combined, at this time detect line position understand because capturing
Colloidal gold and be displayed in red lines.
2, the application method of test paper
(1) aluminium foil bag is opened, Test paper is taken out；
(2) holding strip will have arrow mark line one end to be inserted into blood or urine specimen collection vessel, submerge at least 3 seconds
(note：Depth may not exceed markings horizontal line), it then takes out and keeps flat or be pasted onto test card (replacement of usable record paper), start to count
When observe test result；
(3) red line is waited for occur, observing response is as a result, result judgement is invalid after 30 minutes when should be in 10-30 minutes；
(4) only there are a red stripes in quality control region, red stripes does not occur in detection zone, indicates that result is feminine gender；?
There are two red stripes in quality control region and detection zone, and detection zone color is shallower with respect to quality control region color or two band colors are deep
It is shallow uniform, indicate that result is the positive；When not occurring coloured band in quality control region, show test failure or reagent failure.
3, evaluation
If only there are a red stripes in quality control region, there are not red stripes, indicates in blood sample to be measured in detection zone
APELA concentration APELA concentration in 25ng/ml or more or to be measured urine specimens is detected patient and is sent out with early in 8ng/ml or more
The possibility of type PE is smaller；If there are two red stripes in check plot and detection zone, APELA in blood sample to be measured is indicated
APELA concentration is within the scope of 0-8ng/ml within the scope of 0-25ng/ml or in urine specimen to be measured for concentration, and tested patient is with early
The possibility of hair style PE is larger.
To sum up, Early onset preeclampsia rapid screening test paper provided by the invention and kit, can be to be checked pregnant with screening
Whether woman suffers from Early onset preeclampsia：If APELA concentration in a concentration of 0-25ng/ml of APELA or urine in subject's blood
Within the scope of 0-8ng/ml, it is determined that the risk that person to be checked suffers from Early onset preeclampsia is big；Conversely, then suffering from Early onset preeclampsia
Risk it is small.Test paper of the present invention and kit only need acquisition blood samples of patients or urine, so that it may which whether screening patient is with late hair style
Preeclampsia can be used for clinical assistant diagnosis, can noninvasive, effectively and quickly screening Early onset preeclampsia, it is easy to use,
Potential applicability in clinical practice is good.
Claims (10)
1. a kind of Early onset preeclampsia screening test paper, it is characterised in that：It includes optional for detecting blood or urine
The test paper of middle APELA concentration.
2. screening test paper according to claim 1, it is characterised in that：APELA concentration in the detection blood or urine
Test paper be colloidal gold detection test paper.
3. colloidal gold detection test paper according to claim 2, it is characterised in that：It includes PVC bottom plates and cellulose nitrate
Plain film, nitrocellulose filter are arranged on PVC bottom plates, further include the sample pad being successively set on nitrocellulose filter, colloid
Gold pad, detection zone, quality control region and water absorption pad.
4. colloidal gold detection test paper according to claim 3, it is characterised in that：One layer is provided in the colloidal gold pad
The APELA polyclonal antibody layers of colloid gold label.
5. colloidal gold detection test paper according to claim 3, it is characterised in that：One layer is provided on the detection zone
APELA artificial antigen layers.
6. colloidal gold detection test paper according to claim 3, it is characterised in that：The quality control region is provided with one layer of goat-anti
Rabbit antibody layer.
7. a kind of Early onset preeclampsia screening kit, it is characterised in that：It includes optional for detecting blood or urine
The reagent of APELA concentration in liquid.
8. screening kit according to claim 7, it is characterised in that：APELA is dense in the detection blood or urine
The reagent of degree is ELISA detection reagents.
9. purposes of the test paper of APELA concentration in blood or urine in preparing Early onset preeclampsia screening test paper is detected,
The test paper of APELA concentration is colloidal gold detection test paper in the detection blood or urine.
10. purposes of the reagent of APELA concentration in blood or urine in preparing Early onset preeclampsia screening reagent is detected,
The reagent of APELA concentration is ELISA detection reagents in the detection blood or urine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018103076994 | 2018-04-08 | ||
| CN201810307699 | 2018-04-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108776226A true CN108776226A (en) | 2018-11-09 |
| CN108776226B CN108776226B (en) | 2021-03-19 |
Family
ID=64028022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810541008.7A Active CN108776226B (en) | 2018-04-08 | 2018-05-30 | Test paper and kit for rapidly screening early-stage eclampsia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108776226B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103109192A (en) * | 2010-06-18 | 2013-05-15 | 塞尚公司 | Markers for the prognosis and risk assessment of pregnancy-induced hypertension and preeclampsia |
| WO2014135488A1 (en) * | 2013-03-04 | 2014-09-12 | Iq Products B.V. | Prognostic marker to determine the risk for early-onset preeclampsia |
| CN104136924A (en) * | 2011-12-15 | 2014-11-05 | 普罗诺塔股份有限公司 | Biomarkers and parameters for hypertensive disorders of pregnancy |
| CN106796241A (en) * | 2014-09-02 | 2017-05-31 | 沃拉克有限公司 | The method for determining preeclampsia risk |
| CN107430134A (en) * | 2015-03-16 | 2017-12-01 | A1M制药公司 | The biomarker of preeclampsia |
| WO2017217844A1 (en) * | 2016-06-15 | 2017-12-21 | Iq Products B.V. | Markers and their ratio to determine the risk for early-onset preeclampsia |
| WO2018013053A1 (en) * | 2016-07-15 | 2018-01-18 | Agency For Science, Technology And Research | Methods of diagnosis and treatment of pre-eclampsia |
-
2018
- 2018-05-30 CN CN201810541008.7A patent/CN108776226B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103109192A (en) * | 2010-06-18 | 2013-05-15 | 塞尚公司 | Markers for the prognosis and risk assessment of pregnancy-induced hypertension and preeclampsia |
| CN104136924A (en) * | 2011-12-15 | 2014-11-05 | 普罗诺塔股份有限公司 | Biomarkers and parameters for hypertensive disorders of pregnancy |
| WO2014135488A1 (en) * | 2013-03-04 | 2014-09-12 | Iq Products B.V. | Prognostic marker to determine the risk for early-onset preeclampsia |
| CN106796241A (en) * | 2014-09-02 | 2017-05-31 | 沃拉克有限公司 | The method for determining preeclampsia risk |
| CN107430134A (en) * | 2015-03-16 | 2017-12-01 | A1M制药公司 | The biomarker of preeclampsia |
| WO2017217844A1 (en) * | 2016-06-15 | 2017-12-21 | Iq Products B.V. | Markers and their ratio to determine the risk for early-onset preeclampsia |
| WO2018013053A1 (en) * | 2016-07-15 | 2018-01-18 | Agency For Science, Technology And Research | Methods of diagnosis and treatment of pre-eclampsia |
Non-Patent Citations (5)
| Title |
|---|
| LENA HO等: "ELABELA deficiency promotes preeclampsia and cardiovascular malformations in mice", 《SCIENCE》 * |
| NATASHA PITCHARD 等: "ELABELA/APELA levels are not decreased in the maternal circulation or placenta among women with preeclampsia", 《THE AMERICAN JOURNAL OF PATHOLOGY》 * |
| NATHALIE ACESTOR等: "Towards biomarker-based tests that can facilitate decisions about prevention and management of preeclampsia in low-resource settings", 《CLIN CHEM LAB MED》 * |
| OROMA B. NWANODI: "Preeclampsia-eclampsia adverse outcomes reduction: the preeclampsia-eclampsia checklist", 《HEALTHCARE》 * |
| 康熙雄主编: "《免疫胶体金技术临床应用》", 31 August 2010, 军事医学科学出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108776226B (en) | 2021-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7892774B2 (en) | Diagnostic method for determining the susceptibility to delivery and reagent kit for use therefor | |
| EP1360497B1 (en) | Urine assay for ovarian reserve | |
| JPH06504841A (en) | Method for detecting rupture of fetal membranes and test kit utilizing the method | |
| US20090305436A1 (en) | Device and method for detection of a pregnancy associated hormone | |
| US20090227036A1 (en) | Method of diagnosis of pregnancy-related complications | |
| JPH09506173A (en) | Prenatal meconium detection | |
| US20110065139A1 (en) | diagnostic device for identifying rupture of membrane during pregnancy | |
| DE19806185C2 (en) | Immunoassay and test kit for the determination of fucosylated protein in a biological sample | |
| CN117452002A (en) | Human chorionic gonadotrophin colloidal gold detection test strip and kit for urine saliva simultaneous detection | |
| US20130177485A1 (en) | Diagnostic device for identifying rupture of membrane during pregnancy | |
| SEPPÄLÄ | Immunologic detection of alpha fetoprotein as a marker of fetal pathology | |
| WO2009050711A2 (en) | A diagnostic device for identifying rupture of membrane during pregnancy | |
| CN108776226A (en) | Early onset preeclampsia rapid screening test paper and kit | |
| Seki et al. | Advances in the clinical laboratory detection of gestational trophoblastic disease | |
| CN212808318U (en) | Test strip for detecting fetal fibronectin and human insulin-like growth factor binding protein-1 and device comprising same | |
| JP2000193662A (en) | Measuring reagent for cystatin c in urine, diagnostic method and kit | |
| CN114660285A (en) | Kit for measuring preeclampsia, preparation method and application | |
| CN103175959B (en) | A kind of preparation method detecting premature rupture of fetal membranes immune chromatography test paper | |
| CN103235134B (en) | A kind of immune chromatography test paper detecting premature rupture of fetal membranes and preparation method thereof | |
| CN206300957U (en) | A kind of early pregnancy test strips that can simultaneously detect serum and urine specimen | |
| CA2206420A1 (en) | Use of ligands specific to major histo-compatibility complex-class i antigens for diagnosing endometriosis | |
| CN103293310B (en) | A kind of kit detecting premature rupture of fetal membranes | |
| CN116298319B (en) | Test strip for combined detection of human Tg and Cyfra21-1 | |
| Yamada et al. | Rapid diagnosis of premature rupture of membranes using a new kit employing anti-AFP monoclonal antibody | |
| CN103197068B (en) | A kind of preparation method detecting premature rupture of fetal membranes immune chromatography test paper |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |